Research posters

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 22 posts
May 18, 2020 | Research posters

ISPOR Annual 2020: The Resultant Impact of HEOR Data on US Payer Formulary Coverage

A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.

May 18, 2020 | Research posters

ISPOR Annual 2020: Collaborative Approaches to Attain Healthcare Sustainability in Latin America

This research poster aims to identify hurdles to achieving healthcare sustainability in LA, review approaches taken by policy makers to control healthcare budgets and propose actionable solutions to attain sustainability that mutually benefit healthcare systems and industry.

May 18, 2020 | Research posters

ISPOR Annual 2020: OCM to OCF: Implications for Total Cost of Care

A research poster that aims to map the limitations of the OCM to the proposed features of the 2021 OCF model in order to evaluate whether the OCF is more likely to successfully reduce total cost of care.

May 18, 2020 | Research posters

ISPOR Annual 2020: Evaluating the HTA Impact of Real-World Evidence from Formal Orphan Drug Registries

This research poster aims to perform a comparative assessment of the formal registry requirements in Germany and Brazil for orphan therapies with limited clinical evidence in order to pinpoint the future role of real-world evidence (RWE) in health technology assessments (HTAs).

ISPOR EU 2019: Access to Oncology Therapies in Russia and Visegrad Group Countries Infographic
November 4, 2019 | Research posters

ISPOR EU 2019: ICER – the Similarities and Differences Between UK (England) and USA Cost-Effectiveness Watchdogs

ISPOR EU 2019: CBPartners' EU Center of Excellence presented a poster which explores the similarities and differences between English and US cost-effectiveness watchdogs.